Concepts (185)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hemophilia A | 10 | 2022 | 47 | 1.490 |
Why?
|
| Hemorrhage | 8 | 2021 | 73 | 0.610 |
Why?
|
| Hemophilia B | 4 | 2020 | 10 | 0.460 |
Why?
|
| Purpura, Thrombotic Thrombocytopenic | 2 | 2023 | 9 | 0.450 |
Why?
|
| Factor VIII | 7 | 2023 | 31 | 0.400 |
Why?
|
| Venous Thromboembolism | 3 | 2020 | 32 | 0.340 |
Why?
|
| Heparin | 2 | 2020 | 22 | 0.330 |
Why?
|
| Hemarthrosis | 3 | 2021 | 21 | 0.320 |
Why?
|
| Anticoagulants | 2 | 2020 | 82 | 0.310 |
Why?
|
| Pipecolic Acids | 1 | 2008 | 1 | 0.290 |
Why?
|
| Factor IX | 2 | 2020 | 6 | 0.290 |
Why?
|
| Thrombocytopenia | 1 | 2008 | 21 | 0.290 |
Why?
|
| Autoantibodies | 3 | 2006 | 62 | 0.290 |
Why?
|
| Recombinant Proteins | 3 | 2017 | 162 | 0.270 |
Why?
|
| Humans | 26 | 2023 | 22823 | 0.250 |
Why?
|
| Exercise Therapy | 1 | 2006 | 84 | 0.230 |
Why?
|
| von Willebrand Factor | 4 | 2023 | 11 | 0.230 |
Why?
|
| Thrombophilia | 2 | 2020 | 6 | 0.220 |
Why?
|
| Adult | 13 | 2023 | 6896 | 0.220 |
Why?
|
| Hemostasis | 2 | 2016 | 11 | 0.220 |
Why?
|
| Blood Coagulation Disorders | 1 | 2004 | 13 | 0.210 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2004 | 15 | 0.210 |
Why?
|
| Hemostatics | 1 | 2023 | 11 | 0.210 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2020 | 28 | 0.190 |
Why?
|
| Sex Chromosome Disorders | 1 | 2022 | 1 | 0.190 |
Why?
|
| Leukemia, Promyelocytic, Acute | 1 | 2002 | 5 | 0.190 |
Why?
|
| Hematologic Diseases | 1 | 2002 | 10 | 0.180 |
Why?
|
| Young Adult | 7 | 2023 | 1647 | 0.180 |
Why?
|
| Adolescent | 7 | 2023 | 1874 | 0.180 |
Why?
|
| Physical Therapists | 1 | 2021 | 5 | 0.170 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2020 | 36 | 0.170 |
Why?
|
| Treatment Adherence and Compliance | 1 | 2020 | 3 | 0.160 |
Why?
|
| Serum Albumin | 1 | 2020 | 21 | 0.160 |
Why?
|
| Genetic Variation | 2 | 2017 | 68 | 0.160 |
Why?
|
| Autoimmune Diseases | 3 | 2006 | 26 | 0.160 |
Why?
|
| Health Literacy | 1 | 2021 | 84 | 0.150 |
Why?
|
| Anemia, Sickle Cell | 1 | 2018 | 12 | 0.140 |
Why?
|
| Erythrocyte Transfusion | 1 | 2018 | 12 | 0.140 |
Why?
|
| Factor VIIa | 1 | 2017 | 8 | 0.140 |
Why?
|
| von Willebrand Disease, Type 2 | 1 | 2017 | 1 | 0.130 |
Why?
|
| Blood Coagulation | 1 | 2017 | 20 | 0.130 |
Why?
|
| Joint Diseases | 1 | 2018 | 87 | 0.130 |
Why?
|
| Male | 11 | 2023 | 12400 | 0.130 |
Why?
|
| von Willebrand Disease, Type 1 | 1 | 2016 | 1 | 0.120 |
Why?
|
| Albumins | 1 | 2016 | 18 | 0.120 |
Why?
|
| Child | 4 | 2023 | 1153 | 0.120 |
Why?
|
| Middle Aged | 8 | 2020 | 7873 | 0.120 |
Why?
|
| Arthroplasty, Replacement, Knee | 2 | 2012 | 561 | 0.110 |
Why?
|
| Arthroplasty, Replacement, Hip | 2 | 2012 | 686 | 0.110 |
Why?
|
| Blood Coagulation Factors | 2 | 2006 | 19 | 0.110 |
Why?
|
| United States | 4 | 2018 | 1762 | 0.090 |
Why?
|
| Female | 7 | 2023 | 12904 | 0.090 |
Why?
|
| Megakaryocyte Progenitor Cells | 1 | 2011 | 1 | 0.090 |
Why?
|
| Dipeptidyl Peptidase 4 | 1 | 2011 | 4 | 0.090 |
Why?
|
| Blood Loss, Surgical | 2 | 2011 | 53 | 0.080 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2020 | 97 | 0.080 |
Why?
|
| Arginine | 1 | 2008 | 17 | 0.070 |
Why?
|
| Thromboembolism | 1 | 2008 | 17 | 0.070 |
Why?
|
| Sulfonamides | 1 | 2008 | 45 | 0.070 |
Why?
|
| Risk Factors | 3 | 2020 | 1966 | 0.070 |
Why?
|
| Clinical Trials as Topic | 1 | 2008 | 190 | 0.070 |
Why?
|
| Liver | 1 | 2008 | 136 | 0.070 |
Why?
|
| Interferon-alpha | 1 | 2007 | 30 | 0.060 |
Why?
|
| Polyethylene Glycols | 1 | 2007 | 35 | 0.060 |
Why?
|
| Hepatitis C, Chronic | 1 | 2007 | 42 | 0.060 |
Why?
|
| Treatment Outcome | 3 | 2016 | 2934 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2017 | 312 | 0.060 |
Why?
|
| Ankle Joint | 1 | 2006 | 35 | 0.060 |
Why?
|
| Paraneoplastic Syndromes | 1 | 2006 | 4 | 0.060 |
Why?
|
| Anemia, Hemolytic | 1 | 2005 | 4 | 0.060 |
Why?
|
| Microcirculation | 1 | 2005 | 25 | 0.060 |
Why?
|
| Syndrome | 1 | 2005 | 66 | 0.060 |
Why?
|
| Phenotype | 2 | 2017 | 255 | 0.060 |
Why?
|
| Fever | 1 | 2005 | 32 | 0.060 |
Why?
|
| Pneumonectomy | 1 | 2006 | 76 | 0.060 |
Why?
|
| Kidney Diseases | 1 | 2005 | 68 | 0.060 |
Why?
|
| von Willebrand Diseases | 1 | 2005 | 1 | 0.060 |
Why?
|
| Quality of Life | 2 | 2020 | 559 | 0.060 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type I | 1 | 2004 | 3 | 0.060 |
Why?
|
| Trophoblasts | 1 | 2004 | 2 | 0.060 |
Why?
|
| Deamino Arginine Vasopressin | 1 | 2005 | 5 | 0.060 |
Why?
|
| Adenocarcinoma | 1 | 2006 | 132 | 0.060 |
Why?
|
| Elbow Joint | 1 | 2006 | 113 | 0.060 |
Why?
|
| Diagnosis, Differential | 1 | 2005 | 309 | 0.060 |
Why?
|
| Nervous System Diseases | 1 | 2005 | 99 | 0.050 |
Why?
|
| Inflammation Mediators | 1 | 2004 | 58 | 0.050 |
Why?
|
| Hemorrhagic Disorders | 1 | 2004 | 1 | 0.050 |
Why?
|
| Paraproteins | 1 | 2004 | 1 | 0.050 |
Why?
|
| Fibrin | 1 | 2004 | 4 | 0.050 |
Why?
|
| Biopolymers | 1 | 2004 | 4 | 0.050 |
Why?
|
| Autoantigens | 1 | 2004 | 15 | 0.050 |
Why?
|
| Surveys and Questionnaires | 2 | 2021 | 1019 | 0.050 |
Why?
|
| Apoptosis | 1 | 2004 | 180 | 0.050 |
Why?
|
| Comorbidity | 2 | 2018 | 426 | 0.050 |
Why?
|
| ADAMTS13 Protein | 1 | 2023 | 5 | 0.050 |
Why?
|
| Pregnancy | 2 | 2020 | 324 | 0.050 |
Why?
|
| Follow-Up Studies | 2 | 2023 | 1412 | 0.050 |
Why?
|
| Plasma | 1 | 2023 | 13 | 0.050 |
Why?
|
| Hip Joint | 1 | 2006 | 241 | 0.050 |
Why?
|
| Range of Motion, Articular | 1 | 2006 | 564 | 0.050 |
Why?
|
| ADAM Proteins | 1 | 2023 | 41 | 0.050 |
Why?
|
| Aged, 80 and over | 2 | 2017 | 3717 | 0.050 |
Why?
|
| Lipoproteins | 1 | 2022 | 10 | 0.050 |
Why?
|
| Aged | 3 | 2020 | 7412 | 0.050 |
Why?
|
| Prospective Studies | 2 | 2017 | 1487 | 0.050 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2022 | 83 | 0.050 |
Why?
|
| Immune Tolerance | 1 | 2001 | 12 | 0.050 |
Why?
|
| Child, Preschool | 1 | 2023 | 563 | 0.050 |
Why?
|
| Elective Surgical Procedures | 2 | 2012 | 32 | 0.050 |
Why?
|
| Knee Joint | 1 | 2006 | 566 | 0.040 |
Why?
|
| Lung Neoplasms | 1 | 2006 | 534 | 0.040 |
Why?
|
| Heparin, Low-Molecular-Weight | 1 | 2020 | 4 | 0.040 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2001 | 95 | 0.040 |
Why?
|
| North America | 1 | 2020 | 32 | 0.040 |
Why?
|
| Shoulder Joint | 1 | 2006 | 513 | 0.040 |
Why?
|
| Infusions, Intravenous | 1 | 2020 | 49 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2021 | 370 | 0.040 |
Why?
|
| Retrospective Studies | 2 | 2023 | 2976 | 0.040 |
Why?
|
| Hemoglobin, Sickle | 1 | 2018 | 1 | 0.040 |
Why?
|
| Iron Overload | 1 | 2018 | 2 | 0.040 |
Why?
|
| Blood Viscosity | 1 | 2018 | 9 | 0.040 |
Why?
|
| Disease Management | 1 | 2018 | 98 | 0.030 |
Why?
|
| Platelet Glycoprotein GPIb-IX Complex | 1 | 2017 | 4 | 0.030 |
Why?
|
| Homozygote | 1 | 2017 | 13 | 0.030 |
Why?
|
| Protein Multimerization | 1 | 2017 | 13 | 0.030 |
Why?
|
| Pedigree | 1 | 2017 | 50 | 0.030 |
Why?
|
| Cross-Over Studies | 1 | 2017 | 64 | 0.030 |
Why?
|
| Headache | 1 | 2017 | 36 | 0.030 |
Why?
|
| HEK293 Cells | 1 | 2017 | 58 | 0.030 |
Why?
|
| Transfection | 1 | 2017 | 114 | 0.030 |
Why?
|
| Collagen | 1 | 2017 | 79 | 0.030 |
Why?
|
| Protein Binding | 1 | 2017 | 106 | 0.030 |
Why?
|
| Anxiety | 1 | 2018 | 143 | 0.030 |
Why?
|
| Heterozygote | 1 | 2017 | 88 | 0.030 |
Why?
|
| Administration, Intravenous | 1 | 2016 | 22 | 0.030 |
Why?
|
| Demography | 1 | 2016 | 56 | 0.030 |
Why?
|
| Comparative Genomic Hybridization | 1 | 2016 | 2 | 0.030 |
Why?
|
| Blood Coagulation Tests | 1 | 2016 | 11 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2017 | 258 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2017 | 481 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 1 | 2016 | 48 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2018 | 759 | 0.030 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2018 | 311 | 0.030 |
Why?
|
| Depression | 1 | 2018 | 368 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2017 | 795 | 0.030 |
Why?
|
| Early Ambulation | 1 | 2011 | 14 | 0.020 |
Why?
|
| Intermittent Pneumatic Compression Devices | 1 | 2011 | 5 | 0.020 |
Why?
|
| Ultrasonography, Doppler, Duplex | 1 | 2011 | 14 | 0.020 |
Why?
|
| Vena Cava Filters | 1 | 2011 | 7 | 0.020 |
Why?
|
| Anesthesia, Epidural | 1 | 2011 | 18 | 0.020 |
Why?
|
| Venous Thrombosis | 1 | 2011 | 39 | 0.020 |
Why?
|
| Cell Division | 1 | 2011 | 79 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2011 | 102 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2012 | 235 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2012 | 203 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2011 | 281 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2011 | 276 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2011 | 363 | 0.020 |
Why?
|
| Mice | 1 | 2011 | 1228 | 0.020 |
Why?
|
| Partial Thromboplastin Time | 1 | 2006 | 6 | 0.020 |
Why?
|
| Carboplatin | 1 | 2006 | 24 | 0.020 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2006 | 15 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2011 | 810 | 0.020 |
Why?
|
| Cyclophosphamide | 1 | 2006 | 44 | 0.020 |
Why?
|
| Paclitaxel | 1 | 2006 | 49 | 0.010 |
Why?
|
| Hyperglycemia | 1 | 2006 | 27 | 0.010 |
Why?
|
| Prednisone | 1 | 2006 | 64 | 0.010 |
Why?
|
| Bleeding Time | 1 | 2005 | 1 | 0.010 |
Why?
|
| Drug Evaluation | 1 | 2005 | 19 | 0.010 |
Why?
|
| Immunosuppressive Agents | 1 | 2006 | 111 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2006 | 294 | 0.010 |
Why?
|
| Placenta | 1 | 2004 | 5 | 0.010 |
Why?
|
| Administration, Intranasal | 1 | 2005 | 26 | 0.010 |
Why?
|
| Pre-Eclampsia | 1 | 2004 | 7 | 0.010 |
Why?
|
| Sampling Studies | 1 | 2004 | 23 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2004 | 75 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 2006 | 350 | 0.010 |
Why?
|
| Gestational Age | 1 | 2004 | 73 | 0.010 |
Why?
|
| Reference Values | 1 | 2004 | 169 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2006 | 240 | 0.010 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2006 | 147 | 0.010 |
Why?
|
| Animals | 1 | 2011 | 3255 | 0.010 |
Why?
|
| Cytokines | 1 | 2004 | 202 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2004 | 463 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2004 | 439 | 0.010 |
Why?
|